Novartis Pelacarsen Miss Raises the Bar for Amgen and Eli Lilly

Key Takeaways

Novartis has exposed the central risk in the multibillion-dollar Lp(a) drug race: lowering a biomarker does not establish that patients will suffer fewer heart attacks and strokes. Pelacarsen reduced Lp(a) in a late-stage trial of more than 8,000 patients but failed to deliver a statistically significant improvement in cardiovascular outcomes.

The result puts pelacarsen’s projected $4 billion to $5 billion in peak annual sales at risk and raises the proof threshold for Amgen and Eli Lilly. Their drugs have produced deeper Lp(a) reductions using different technologies, but only outcomes data can determine whether that additional potency changes cardiovascular risk.

What Happened

Novartis said after Friday’s close that pelacarsen missed the cardiovascular-outcomes objective in its late-stage study despite lowering Lp(a). Lp(a), short for lipoprotein(a), is a genetically determined cholesterol-carrying particle associated with arterial plaque, blood clotting and elevated cardiovascular risk; no targeted treatment is currently approved.

The clinical distinction is decisive. A drug can move a laboratory measure yet fail to improve patient outcomes if the reduction is too small, treatment starts too late, the enrolled population is poorly suited to show a benefit or the biological relationship does not translate into an effective intervention. The topline announcement does not disclose enough evidence to distinguish among those explanations.

Novartis plans to present complete results at an upcoming medical congress. Investors still need the magnitude of Lp(a) lowering, the observed change in cardiovascular risk, event counts, confidence intervals and subgroup results. Barclays noted that Novartis had previously indicated that a 13% benefit could have been statistically significant in the overall population and interpreted the limited release as suggesting pelacarsen fell materially short of that threshold.

Background & Context

Lp(a) was discovered in 1963, and researchers nearly 50 years later found that people with elevated levels faced more than twice the risk of a heart attack. Elevated Lp(a) is estimated to affect roughly one in five people worldwide. Unlike LDL cholesterol, its level is determined almost entirely by genetics and is largely unaffected by diet or exercise.

That combination of prevalence, cardiovascular risk and lack of an approved targeted therapy created the premise for a market expected to be worth billions of dollars. Analysts had modeled approximately $4 billion to $5 billion in peak annual sales for pelacarsen if it succeeded.

The opportunity matters to Novartis because Entresto, its bestselling heart drug, has lost key patent exclusivities, while additional blockbuster products are approaching generic competition. Chief Executive Vas Narasimhan has described the period as the steepest patent cliff in the company’s history. The trial miss does not establish that pelacarsen’s program has ended, but it places the projected growth contribution under substantial doubt.

The study also illustrates the cost of progress in cardiovascular medicine. Novartis said the more than 8,000 participants were already receiving optimized care. Jefferies analysts argued that improving standards of care are reducing cardiovascular events, which can leave an experimental therapy with fewer events to prevent and force developers to run larger, longer or more expensive trials to prove an incremental benefit.

Market & Stock Impact

• Novartis: The shares fell 3% on Monday. The relatively contained reaction suggests that investors already viewed the study as risky and expected a moderate rather than transformative benefit, but the miss threatens a potential $4 billion-to-$5 billion peak-sales opportunity during a demanding patent cycle.
• Ionis Pharmaceuticals: Ionis shares sank 10% in extended Friday trading. As pelacarsen’s joint developer, Ionis has direct program exposure, making the undisclosed efficacy details more consequential than a general read-through from another company’s asset.
• Amgen: Amgen fell about 5% in extended trading because Citi identified olpasiran as facing the clearest read-through. Its technology has shown deeper Lp(a) lowering, but Citi said later studies now face greater pressure to demonstrate a clinically meaningful reduction of roughly 15% in major adverse cardiovascular events.
• Eli Lilly: Lepodisiran is being studied in a broader population that includes some people without established cardiovascular disease, potentially limiting direct comparison with the Novartis study. Citi also described the program as less material to Lilly’s overall valuation, tempering the company-level impact without removing the clinical uncertainty.
• NewAmsterdam Pharma: The Netherlands-based company’s U.S.-listed shares fell 12% in extended Friday trading. Its experimental treatment also aims to reduce cardiovascular events by lowering Lp(a), so investors applied a class-wide risk discount even though the competing approaches are not identical.

Investor Checkpoints

• Pelacarsen’s full presentation: At the upcoming medical congress, compare the percentage decline in Lp(a) with the change in cardiovascular events. The result should indicate whether pelacarsen produced inadequate target suppression or whether substantial suppression still failed to help patients.
• Distance from significance: Examine event counts, confidence intervals and subgroup findings alongside the previously cited 13% benefit threshold. A narrowly missed study would have a different implication for competing drugs than a result showing little or no clinical effect.
• Amgen’s outcomes evidence: Test olpasiran’s deeper biomarker reduction against the roughly 15% decline in major adverse cardiovascular events highlighted by Citi. Starting Lp(a) levels, adherence and background therapy will affect whether the comparison with pelacarsen is informative.
• Lilly’s broader enrollment: Assess whether including participants without established cardiovascular disease changes event rates, trial duration and the benefit needed for statistical significance. Broader enrollment may provide different evidence, but a lower event rate could also make efficacy harder to demonstrate.

Outlook

The constructive case remains scientifically plausible but narrower. Pelacarsen may have used a less effective mechanism, lowered Lp(a) by too little or entered a treatment setting where optimized care left limited residual risk. William Blair analysts said drugs capable of deeper reductions could still justify continued development, particularly for patients who begin with very high Lp(a) levels.

The adverse case reaches beyond one asset. Lp(a) may be a strong marker of inherited cardiovascular risk without being a sufficiently powerful treatment target under current trial conditions. If the complete data show a large biomarker reduction accompanied by little change in clinical events, the burden on rival programs will rise sharply.

The upcoming medical-congress presentation is therefore the next defining catalyst. Its clinical-event data—not the headline reduction in Lp(a)—must clarify whether this was principally a pelacarsen problem, a trial-design problem or evidence against the wider therapeutic hypothesis.

FAQ

Why did pelacarsen miss despite lowering Lp(a)?

The reported facts establish that pelacarsen reduced Lp(a) but did not significantly improve cardiovascular outcomes. The available topline release does not show whether the miss resulted from its mechanism, insufficient lowering, trial design, optimized background care or a weakness in the broader Lp(a) hypothesis.

Does the Novartis result mean every Lp(a) drug will fail?

No. Amgen and Eli Lilly are testing different technologies that have produced deeper Lp(a) reductions, while Lilly is studying a broader population. Those distinctions may matter, but neither company can rely on biomarker potency alone after the first dedicated outcomes setback.

Which stocks have the greatest exposure to the pelacarsen setback?

Novartis and Ionis have direct exposure because they jointly developed pelacarsen. Citi identified Amgen’s olpasiran as having the clearest read-through among competing programs, while Lilly’s lepodisiran is less directly comparable and less material to Lilly’s overall valuation.

This article was independently written by OneDayTrading from public reporting. Read the original (CNBC)